![]() | |
Identifiers | |
---|---|
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
DrugBank | |
PubChem CID | |
UNII | |
| |
| |
Properties | |
C62H98N16O22 | |
Molar mass | 1419.556 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Gastric Pentadecapeptide BPC-157 (also known as PL 14736, Body Protection Compound 157, or bepecin) is a fifteen amino acid long oligopeptide that was discovered during research on human gastric juice. [1] The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. [2]
BPC-157 is stable at room temperature and bioavailable in rodent models when administered IM or IV. [3]
Pre-clinical research has indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may also accelerate tissue and organ healing. [4] [5] [6] [7] [8] [9]
This substance is sometimes used in functional medicine despite not being approved by any drug regulatory agency. [10] The compound promotes angiogenesis and as a result has some concerns over cancer promotion. [11] [12]
As of 2022, the peptide is banned by the World Anti-Doping Agency under the S0 category of non-exempt substances. [13]
BPC-157 is detected in urine using a weak cation exchange solid phase extraction and was found to be stable in urine for 4 days. [14]